8-K: Heron Therapeutics Appoints Ira Duarte as Principal Accounting Officer, Replacing Lisa Peraza
Personnel Change Announcement
Heron Therapeutics has announced the appointment of Ira Duarte as its new principal accounting officer, effective March 29, 2024, replacing Lisa Peraza.
Summary
- Heron Therapeutics has designated Ira Duarte as the new principal accounting officer, effective March 29, 2024.
- Lisa Peraza, the current Chief Accounting Officer and principal accounting officer, will be stepping down on the same date.
- Ira Duarte's biographical information is available in a previous 8-K filing from June 8, 2023.
- There are no special arrangements or understandings related to Ms. Duarte's appointment.
- There are no family relationships between Ms. Duarte and any director or executive officer of the company.
- There are no related party transactions between the company and Ms. Duarte that require disclosure.
- Ms. Duarte will not receive any additional compensation for taking on the role of principal accounting officer.
Sentiment
Score: 7
Explanation: The document reflects a routine personnel change with no apparent negative implications. The transition appears to be well-managed and orderly.
Positives
- The transition of the principal accounting officer role appears to be well-planned and orderly.
- There are no apparent conflicts of interest or related party issues associated with the appointment.
Risks
- The departure of a key financial officer, even with a planned transition, could introduce some short-term operational risks.
- Any unforeseen issues during the transition period could potentially impact financial reporting.
Industry Context
Changes in key financial roles are common in the pharmaceutical industry, and this transition appears to be a routine personnel change.
Comparison to Industry Standards
- The transition of a principal accounting officer is a standard operational procedure in publicly traded companies.
- The lack of additional compensation for the new role is not unusual, as it is often part of the existing executive's responsibilities.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| principal accounting officer | Lisa Peraza | Ira Duarte | 2024-03-29 | Lisa Peraza's employment with the company ends on this date. |
Stakeholder Impact
- Shareholders may view this as a routine transition with no significant impact on the company's operations.
- Employees may experience a change in leadership within the accounting department.
Key Dates
| Date | Description |
|---|---|
| 2023-06-08 | Date of previous 8-K filing containing Ira Duarte's biographical information. |
| 2024-03-18 | Date of the report announcing the change in principal accounting officer. |
| 2024-03-29 | Effective date of Ira Duarte's appointment as principal accounting officer and Lisa Peraza's departure. |
Keywords
principal accounting officer, Ira Duarte, Lisa Peraza, executive change, financial officer, Heron Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.